Full Text View
Tabular View
No Study Results Posted
Related Studies
A Study of ALRT 1057 Topical Gel in Patients With AIDS-Related Kaposi's Sarcoma
This study has been completed.
Study NCT00002439   Information provided by NIH AIDS Clinical Trials Information Service
First Received: November 2, 1999   Last Updated: June 23, 2005   History of Changes

November 2, 1999
June 23, 2005
 
 
 
 
Complete list of historical versions of study NCT00002439 on ClinicalTrials.gov Archive Site
 
 
 
A Study of ALRT 1057 Topical Gel in Patients With AIDS-Related Kaposi's Sarcoma
Randomized Phase III Vehicle Controlled Trial of ALRT 1057 Topical Gel in Patients With AIDS-Related Kaposi's Sarcoma

The purpose of this study is to see if ALRT1057 gel is safe and effective in treating Kaposi's sarcoma (KS) when applied to skin .

This is a Phase 3 double-blind study. KS patients are randomized to 1 of 2 treatment arms. They receive either ALRT1057 gel or placebo for 12 weeks. If progressive disease for KS is noted before Week 12, patients are switched to the other blinded treatment arm. If a response or disease progression that has not persisted for at least 4 weeks as of Week 12 occurs, treatment on the blinded arm is continued for up to 4 additional weeks, or until response of disease progression is confirmed. After that time or after 12 weeks of treatment, open-label ALRT1057 may be received.

 
Interventional
Treatment
  • Sarcoma, Kaposi
  • HIV Infections
Drug: Alitretinoin
 
Walmsley S, Northfelt DW, Melosky B, Conant M, Friedman-Kien AE, Wagner B. Treatment of AIDS-related cutaneous Kaposi's sarcoma with topical alitretinoin (9-cis-retinoic acid) gel. Panretin Gel North American Study Group. J Acquir Immune Defic Syndr. 1999 Nov 1;22(3):235-46.

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Completed
 
 
 

Information not available

Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
 
 
NCT00002439
 
272A, L1057T-31, 96ACR-LIG1
Anderson Clinical Research
Ligand Pharmaceuticals
 
NIH AIDS Clinical Trials Information Service
August 1997

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP